Publications scientifiques sur le VIH
Treatment with growth hormone releasing hormone analog reduces VEGF-A, TGFfβ-1, and CSF-1: Mechanisms of tesamorelin effect in nonalcoholic fatty liver disease.
2020
Fourman LT.
Oral presentation #142 at: Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting); November 13-16, 2020; virtual.
Effect of tesamorelin on risk of development or progression of diabetic retinopathy and glycemic control in HIV-infected subjects with diabetes and central adiposity [abstract].
2020
Antiviral Therapy.
Brown TT, Bedimo R, Goss OG, et al.
25(suppl 1):A17. Proceedings of the 22nd International Workshop on Co-morbidities and Adverse Drug Reactions in HIV.
Effect of tesamorelin on risk of development or progression of diabetic retinopathy and glycemic control in HIV-infected subjects with diabetes and central adiposity.
2020
Brown TT, Bedimo R, Goss OG, et al.
Oral presentation at: 22nd International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; November 30-December 4 2020; virtual.
Clinical predictors of liver fibrosis presence and progression in HIV-associated NAFLD [abstract].
2020
Top Antivir Med.
Fourman LT, Stanley TL, Feldpausch M, et al.
28(1):128. Proceedings of the Conference on Retroviruses and Opportunistic Infections, 2020.
Clinical predictors of liver fibrosis presence and progression in HIV-associated NAFLD.
2020
Fourman LT, Stanley TL, Feldpausch M, et al.
Oral presentation #128 at: Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020; Boston, Massachusetts, USA. Session O-10.